Korro Bio, Inc. Board of Directors

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Mr. Ram Aiyar MBA, Ph.D.

Mr. Ram Aiyar MBA, Ph.D.

CEO, President & Director

Mr. Todd Chappell M.B.A.

Mr. Todd Chappell M.B.A.

Chief Operating Officer

Ms. Stephanie Engels

Ms. Stephanie Engels

Senior VP and Head of People & Culture

Mr. Vineet Agarwal M.B.A.

Mr. Vineet Agarwal M.B.A.

Chief Financial Officer

Dr. Jean-Francois Formela M.D., MBA

Dr. Jean-Francois Formela M.D., MBA

Co-Founder & Independent Director

Mr. Nessan Bermingham Ph.D.

Mr. Nessan Bermingham Ph.D.

Co-Founder & Independent Chairman of the Board

Mr. Marco A. Passini Ph.D.

Mr. Marco A. Passini Ph.D.

VP & Head of CNS biology

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.